Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0070664 |
| Name | oropharyngeal squamous cell carcinoma |
| Definition | An oropharynx cancer that derives_from squamous epithelial cells. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Xrefs |
SNOMEDCT_US_2025_09_01:423464009
|
| Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer pharynx cancer oropharynx cancer oropharyngeal squamous cell carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05176483 | Phase I | XL092 Ipilimumab + Nivolumab + XL092 Nivolumab and relatlimab-rmbw + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab | Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors (STELLAR-002) | Active, not recruiting | USA | POL | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 0 |
| NCT06727565 | Phase II | Carboplatin + Paclitaxel + Zimberelimab AB154 + Carboplatin + Paclitaxel + Zimberelimab | Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 (VELOCITY-HNSCC) | Recruiting | USA | ITA | GBR | FRA | ESP | AUS | 3 |
| NCT06980038 | Phase II | CDX-1140 + Cemiplimab Cemiplimab | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer | Recruiting | USA | 0 |
| NCT07276399 | Phase III | Cisplatin + Fluorouracil + Pembrolizumab Carboplatin + Fluorouracil + Pembrolizumab Amivantamab-vmjw + Carboplatin + Pembrolizumab | A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-5) | Recruiting | USA | GBR | BRA | AUS | 3 |
| NCT07346196 | Phase II | Carboplatin + Cemiplimab + Fianlimab + Paclitaxel Carboplatin + Cemiplimab + Paclitaxel | A Randomized Phase II Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck | Not yet recruiting | USA | 0 |